Recent results from BristolMyersSquibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-MyersSquibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves BristolMyersSquibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Some results have been hidden because they may be inaccessible to you